KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Equity Ratio (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Equity Ratio readings, the most recent being 0.65 for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 42.67% to 0.65 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.65, a 42.67% increase, with the full-year FY2025 number at 0.65, up 42.67% from a year prior.
  • Equity Ratio hit 0.65 in Q4 2025 for Esperion Therapeutics, up from 1.24 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.52 in Q4 2021 to a low of 2.21 in Q4 2023.
  • Median Equity Ratio over the past 5 years was 1.15 (2024), compared with a mean of 1.18.
  • Biggest five-year swings in Equity Ratio: plummeted 4610.13% in 2021 and later skyrocketed 48.86% in 2024.
  • Esperion Therapeutics' Equity Ratio stood at 0.52 in 2021, then plummeted by 153.02% to 1.31 in 2022, then plummeted by 69.3% to 2.21 in 2023, then skyrocketed by 48.86% to 1.13 in 2024, then surged by 42.67% to 0.65 in 2025.
  • The last three reported values for Equity Ratio were 0.65 (Q4 2025), 1.24 (Q3 2025), and 1.25 (Q2 2025) per Business Quant data.